Genmab — April 2020
-
JV - ja US tal er til den lave ende, men hvorfor ikke fremhæve de fantatiske RoW tal. Look at the bright side ...
-
High rate of profound clonal and renal responses with Daratumumab treatment in heavily pre‐treated patients with AL amyloidosis and high bone marrow plasma cell infiltrate https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25828
-
-
...fordi det velovervejede argument ikke længere eksisterer
-
Bemærk hvor meget JnJ generelt nedjustere med....BP bliver modsat stort set alle andre tidligere kriser også ramt retr hårdt af det her. Nogen der har hørt interviews der belyser lidt mere hvor det er de regner med at miste omsætning og/eller udgifter der stige
r? -
Er der nogen der ved hvor lang tid, der går før vi hører nyt om godkendelsen af den subkutane version af Darzalex? Jeg ved ikke hvor lang tid en sådan godkendelse normalt tager, men hvis det er ét års tid, så er muligheden der for at den nye løsning er klar inden en eventuel anden bølge af corona. Or am I wrong?:-)
-
@troldmanden they actually see alll of their guidance downgrade coming from the medical devices division; expect a -/- $4bn to $7bn sales impact there, which is roughly the total downgrade
-
thanks E L
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind